Zacks Investment Research Downgrades Exicure (NASDAQ:XCUR) to Hold

Exicure (NASDAQ:XCURGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States. “

XCUR traded down $0.00 during trading on Thursday, hitting $0.12. The company had a trading volume of 64,553 shares, compared to its average volume of 9,962,838. The company has a market capitalization of $14.60 million, a PE ratio of -0.18 and a beta of 1.60. Exicure has a one year low of $0.10 and a one year high of $1.98. The firm’s 50-day moving average price is $0.19 and its 200 day moving average price is $0.31.

Exicure (NASDAQ:XCURGet Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. Equities research analysts predict that Exicure will post -0.15 earnings per share for the current year.

A number of large investors have recently modified their holdings of XCUR. Morgan Stanley increased its stake in shares of Exicure by 34.8% during the 2nd quarter. Morgan Stanley now owns 49,425 shares of the company’s stock worth $74,000 after purchasing an additional 12,751 shares during the last quarter. Raymond James & Associates increased its stake in shares of Exicure by 20.8% during the 3rd quarter. Raymond James & Associates now owns 75,500 shares of the company’s stock worth $91,000 after purchasing an additional 13,000 shares during the last quarter. BlackRock Inc. increased its stake in shares of Exicure by 37.0% during the 3rd quarter. BlackRock Inc. now owns 511,345 shares of the company’s stock worth $614,000 after purchasing an additional 138,050 shares during the last quarter. Prosight Management LP increased its stake in shares of Exicure by 42.4% during the 3rd quarter. Prosight Management LP now owns 5,125,000 shares of the company’s stock worth $6,150,000 after purchasing an additional 1,525,000 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of Exicure by 48.0% during the 3rd quarter. HighTower Advisors LLC now owns 73,867 shares of the company’s stock worth $88,000 after purchasing an additional 23,952 shares during the last quarter. 41.68% of the stock is currently owned by hedge funds and other institutional investors.

About Exicure (Get Rating)

Exicure, Inc, a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen SA to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.

Featured Stories

Get a free copy of the Zacks research report on Exicure (XCUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.